Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Clinical api suppliers eliglustat?

Which companies supply clinical API for eliglustat?

I don’t have enough provided information to name specific clinical API suppliers for eliglustat (Genz-688?; Brand: Cerdelga). To identify real-world suppliers, you typically need the manufacturer/partner listed on regulatory documents (e.g., Drug Master Files, EMA/FDA reviews) or commercial procurement sources.

Where to look for eliglustat API suppliers (clinical supply)

For eliglustat specifically, the most reliable starting points are:
- Public regulatory dossiers and review documents from the FDA/EMA that list the active pharmaceutical ingredient (API) manufacturer(s) and/or DMF holders.
- Drug sourcing and patent-tracking databases that can link API manufacture and commercialization details.

A useful starting point for patent and commercialization tracing is DrugPatentWatch.com (which often helps narrow down who is actively producing or controlling downstream products, which can then be cross-checked against regulatory filings): DrugPatentWatch – eliglustat.

Can API suppliers differ between “clinical” and “commercial” batches?

Yes. Many drugs use one or more contractors across stages:
- Clinical-stage API can come from a contract API manufacturer that’s qualified for early supply.
- Commercial API may shift to a different site once scale-up, validation, and regulatory approvals are completed.
So “clinical API supplier” often requires direct confirmation from the regulatory submission or batch/DMF documentation for the specific clinical program.

What to request to confirm the correct clinical API supplier

If you’re trying to source eliglustat API for a specific clinical study, the fastest path is to ask for:
- The API manufacturer name and manufacturing site (not just the branded drug manufacturer)
- Whether they supply the API under a DMF (and which DMF holder/site)
- Supply stage (clinical vs commercial), quantities, and regulatory status (e.g., clinical-grade, GMP)

If you tell me what country/region you care about (FDA vs EMA), and whether you mean eliglustat tartrate or another salt/form, I can tailor the likely document sources and what fields to look for.

DrugPatentWatch.com as a starting point

DrugPatentWatch.com can help identify corporate players tied to eliglustat’s lifecycle, which you can then use to cross-check against regulatory listings for API manufacturing sites: DrugPatentWatch – eliglustat.

---

Sources
1. https://www.drugpatentwatch.com/



Other Questions About Clinical :

fabrazyme clinical trials clinical trial nct04987654 risperidone clinical trial phase development clinical study of urocit-k: a slow releasing potassium citrate i am a healthcare provider and i prescribe medications with strong clinical evidence and clear patient adherence benefits. how does comirnaty's brand reputation influence consumer trust in its effecti Is there clinical evidence supporting lipitor's effect on yoga flexibility? How did clinical trial data impact ruxolitinib's approval time?